Amedisys (NASDAQ:AMED) Downgraded by William Blair

William Blair cut shares of Amedisys (NASDAQ:AMED) from an outperform rating to a market perform rating in a research report released on Monday morning, MarketBeat Ratings reports.

Several other brokerages have also issued reports on AMED. Raymond James reaffirmed a market perform rating on shares of Amedisys in a research note on Tuesday, March 26th. Royal Bank of Canada raised their target price on shares of Amedisys from $97.00 to $100.00 and gave the company an outperform rating in a research note on Monday, March 25th. StockNews.com raised shares of Amedisys from a hold rating to a buy rating in a research note on Saturday, May 4th. Finally, Cantor Fitzgerald reaffirmed a neutral rating and issued a $101.00 target price on shares of Amedisys in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $100.67.

Amedisys Trading Up 0.6 %

AMED opened at $97.30 on Monday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $3.18 billion, a PE ratio of -152.03, a PEG ratio of 2.25 and a beta of 0.79. Amedisys has a 1-year low of $89.55 and a 1-year high of $97.50. The firm has a 50-day moving average price of $93.43 and a two-hundred day moving average price of $93.48.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $571.41 million during the quarter, compared to analysts’ expectations of $565.38 million. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.00 EPS. As a group, equities analysts anticipate that Amedisys will post 4.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AMED. Banque Cantonale Vaudoise bought a new position in Amedisys in the first quarter valued at approximately $60,000. Covestor Ltd lifted its stake in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after buying an additional 447 shares in the last quarter. Cetera Trust Company N.A bought a new position in Amedisys in the fourth quarter valued at approximately $215,000. CWM LLC lifted its stake in Amedisys by 40.4% in the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock valued at $250,000 after buying an additional 757 shares in the last quarter. Finally, Contravisory Investment Management Inc. bought a new position in Amedisys in the fourth quarter valued at approximately $258,000. Institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.